MicroRNAs (miRNAs) are a class of small single-stranded and highly conserved non-coding RNAs, which are closely linked to cardiac disorders such as myocardial infarction (MI), cardiomyocyte hypertrophy, and heart failure. A growing number of studies have demonstrated that miRNAs determine the fate of the heart by regulating cardiac cell death and regeneration after MI. A deep understanding of the pathophysiology of miRNA dependent regulatory pathways in these processes is required. The role of miRNAs as diagnostic, prognostic, and therapeutic targets also needs to be explored in order to utilize them in clinical settings. This review summarizes the role of miRNAs in myocardial infarction and focuses mainly on their influence on cardiomyocyte regeneration and cell death including apoptosis, necrosis, and autophagy. In addition, the targets of pro- and anti-MI miRNAs are comparatively described. In particular, the possibilities of miRNA-based diagnostic and therapeutic strategies for myocardial infarction are discussed in this review.
Background: Corona virus infection is a respiratory infection, compromising the normal breathing in critical patients by damaging the lungs. Researches are ongoing to find an efficient treatment strategy for this disease by either inactivating the virus or boosting the immune system of patient or by managing the cytokine storm. Aim: To evaluate the clinical outcomes of Substance P receptor Neurokinin 1 antagonist in Covid-19 patients against the usual treatments as controls. Patients and Methods: It is a randomized clinical trial, open label, having two arms, one receiving normal management and care while other receiving Neurokinin-1 Receptor antagonist, Aprepitant, in addition. Dexamethasone, a corticosteroid is also administered orally to both the groups. PCR positive, hospitalized patients with more than 18 years of age, both genders, moderate to critical phase were included. 18 patients were randomly allocated in both arms, having 10 in group A and 8 in group B. Lab investigations were performed in both the groups before and after the intervention. We report preliminary results for the comparison of Aprepitant 80 mg given once daily for 3-5 days vs routine management. The primary outcome was total in hospital days and duration of disease. Results: Mean age of patients in group A was 47.63 ±12.07years while 60.90± 9.75 years in group B. There were 3/8 males in group A and 8/10 in group B. There were 2 critical patients in group A and 5 in group B. Biochemical and hematological parameters in both groups didn’t show much difference except the C-reactive protein reduction in the intervention group, indicative of a reduced inflammation. Oxygen saturation also improved but more patients should be enrolled to get a statistically significant data. One patient was discharged from each group within 5 days and one patient expired in each. Conclusions: It is a pilot study but the findings give a strong clue for the therapeutic potential of Aprepitant. Patients who received a combination therapy of Aprepitant and Dexamethasone were recovered earlier and showed improved clinical outcomes, laboratory findings and reduced C-reactive protein which is an inflammatory marker. We suggest here a study on larger sample size to get a deeper insight of its potential and efficacy. It may be more effective in severe to critical patients having respiratory difficulties.
Spandidos Publications is a scientific publisher with a long-standing international reputation for excellent standards and high quality science publications
CRISPR-Cas9, a revolutionary gene-editing tool, has garnered significant attention in the scientific community and beyond. This innovative technology holds immense promise for precision genome engineering, enabling scientists to modify DNA with unprecedented accuracy. The potential applications of CRISPR-Cas9 are vast, ranging from treating genetic disorders to enhancing agricultural crops. As we delve into the era of personalized medicine and genetic advancements, CRISPR-Cas9 emerges as a game-changer in the field of biotechnology. At the core of CRISPR-Cas9 lies its ability to precisely target and edit specific genes within the genome. This powerful tool utilizes RNA molecules as guides to direct the Cas9 enzyme to the desired DNA sequence, where it makes precise cuts. By introducing modifications or repairs to the DNA at these targeted sites, researchers can potentially correct genetic mutations responsible for diseases. The ability to edit the human genome with such precision offers hope for treating previously incurable genetic disorders and improving patient outcomes. Moreover, CRISPR-Cas9 has implications beyond human health. It has the potential to revolutionize agriculture by enhancing crop resistance to pests, improving yields, and reducing the need for harmful pesticides. By modifying specific genes in plants, scientists can develop crops that are more resilient to environmental stressors, ultimately contributing to global food security and sustainability efforts. Despite its immense potential, CRISPR-Cas9 also raises ethical considerations and concerns. The technology's power to edit the human germline raises questions about the potential for unintended consequences and the need for responsible use. The scientific community and policymakers must engage in thoughtful discussions and establish guidelines to ensure the ethical and responsible implementation of CRISPR-Cas9. CRISPR-Cas9 represents a landmark advancement in precision genome engineering, offering unprecedented opportunities to reshape the future of healthcare and agriculture. By harnessing its potential, we can envision a world where previously untreatable genetic diseases are curable, crops are more resilient and productive, and our understanding of the genetic basis of life is deepened. However, as we embrace the future of CRISPR-Cas9, it is crucial to navigate the ethical implications and ensure responsible use to maximize the benefits and minimize potential risks. The potential of this transformative technology is immense, and its impact on society will be profound.
In the recent years, the field of lab-on-a-chip (LOC) technology has made substantial progress and has transformed the landscape of diagnostic applications. These miniaturized and integrated microfluidic devices have potentially revolutionized medical diagnostics by providing rapid, sensitive, and cost-effective analysis of various biomarkers and analytes. One of the key advancements in this domain is the integration of cellular constructs within micro-engineered platforms. It has enabled to recapitulate the physiological and pathological conditions of complex tissues and organs. This ‘Organ-on-a-Chip’ technology holds immense promise for point-of-care diagnostics. These microfluidic devices offer unprecedented insights into disease mechanisms and therapeutic interventions. From mimicking the blood-brain barrier for drug screening to representing the properties of vital organs like the liver, heart, and lungs, organ-on-a-chip systems can revolutionize diagnostic paradigms. Not only has this technology enhanced the diagnostic accuracy, it is also revolutionizing multiplexing and high-throughput screening. These micro-engineered constructs provide a versatile platform for drug development and toxicology studies, and enable researchers to evaluate multiple parameters simultaneously, which has accelerated the pace of discovery and innovation. In additions, these systems are potentially streamlining the sample preparation and analysis as well. Owing to their miniaturized nature, the organ-on-a-chip devices allow for the use of smaller sample and reagent volumes, leading to more efficient and cost-effective analyses. Despite the impressive strides made in organ-on-a-chip technology, there are still challenges need to be addressed. Among these hurdles lie standardization, scalability, and regulatory considerations that must be overcome to fully realize the potential of these micro-engineered platforms. However, continued innovation and collaboration can totally alter the future of diagnostic applications. Organ-on-a-chip technology holds the promise of revolutionizing medical diagnostics, offering rapid, sensitive, and cost-effective analysis of biomarkers and analytes. The potential for organ-on-a-chip technology to transform healthcare delivery and improve patient outcomes is limitless
30 June 2022 in NURSEARCHER (Journal of Nursing & Midwifery Sciences)
Urinary tract infection (UTI) is a common bacterial infection that can progress to septicemia, a serious and potentially life-threatening condition. Septicemia occurs when bacteria from an infection in one part of the body spread to the bloodstream and cause a systemic inflammatory response. Early recognition and treatment of septicemia in UTI is crucial to prevent serious complications and improve outcomes. Objective: To explore the complications and outcomes of septicemia in UTI. Methods: The cross-sectional, descriptive, and observational. 101 patients with septicemia due to UTI were enrolled from the medical wards and Accident and Emergency Department of Mayo Hospital Lahore. Liver function tests, renal function tests, and full blood counts were performed on each patient. Data were entered into a Performa created for this study, and the latest SPSS version was used for data analysis. Results: Majority of males and females had normal bilirubin and Na+ and K+ levels. WBCs were high in 13/16 males and14/16 females. Platelets were low in 9/16 males but normal in 9/16 females. Hemoglobin. Conclusions: Septicemia in UTI is a serious and potentially life-threatening complication. Early recognition and treatment of septicemia is crucial to prevent serious complications and improve outcomes